Overnight Switch from Rasagiline to Safinamide in Parkinson's Disease Patients with Motor Fluctuations: a Tolerability and Safety Study.

When switching between monoamine oxidase type B (MAO‐B) inhibitors, a 15‐day suspension period is a precautionary measure to avoid a serotonin syndrome and hypertensive crisis. However, this indication results in a major inconvenience for parkinsonian patients because of the worsening of their clinical condition. In routine clinical practice, neurologists often perform a substitution of these two drugs without solution of continuity (i.e. overnight), to avoid worsening of fluctuations and prolonged OFF periods. Therefore, a safety open label study was performed to investigate the possible risks of switching overnight from rasagiline to safinamide.